Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30421484 | 1.00 | POLB (0.61) | POLBLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL535878 | 0.87 | POLB (0.72) | POLBLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL29965768 | 0.87 | POLB (0.72) | POLBLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL1549127 | 0.87 | POLB (0.82) | POLBLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL4510662 | 0.86 | LMNA (0.65) | POLBLMNAALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL2434452 | 0.86 | POLB (0.70) | POLBLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL30542063 | 0.85 | KDM4E (0.71) | POLBLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL10341064 | 0.85 | KDM4E (0.71) | POLBLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL11101956 | 0.84 | LMNA (0.56) | POLBLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL6313804 | 0.82 | LMNA (0.62) | LMNAALDH1A1KDM4EMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | US | disclosed |
| US-20200338063-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-10231932-B2 | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3216787-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-03 | — | — | US | disclosed |
| EP-0494978-B1 | HETEROCYCLIC COMPOUNDS | WYETH JOHN & BROTHER LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5362734-A | Certain benzo-quinolizine compounds and derivatives thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-11-08 | — | — | US | disclosed |
| US-5225419-A | Antagonist 5-hydroxytryptamine for treatment of nausea or vomiting | JOHN WYETH & BROTHER, LIMITED (GB) | 1993-07-06 | — | — | US | disclosed |
| EP-0494978-A1 | HETEROCYCLIC COMPOUNDS. | WYETH JOHN & BROTHER LTD (GB) | 1992-07-22 | — | — | EP | disclosed |
| US-5096901-A | PHARMACOLOGICALLY ACTIVE AMIDES AND ESTERS CONTAINING AN AZABICYCLOALKANE MOIETY | JOHN WYETH & BROTHER LIMITED (GB) | 1992-03-17 | — | — | US | disclosed |
| WO-1991005783-A1 | HETEROCYCLIC COMPOUNDS | JOHN WYETH & BROTHER LIMITED (GB) | 1991-05-02 | — | — | WO | disclosed |
| EP-0172004-B1 | QUINOLINONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | The Boots Company PLC (GB) | 1990-03-21 | — | — | EP | disclosed |
| US-4698350-A | 1-ethyl-6-fluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxylic acid and antibacterial use thereof | STERLING DRUG INC. (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0179239-A2 | 7-(Pyridinyl)-/-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid having antibacterial activity and preparation thereof | STERLING DRUG INC. (US) | 1986-04-30 | — | — | EP | disclosed |
| EP-0168733-A2 | Process for the preparation of quinolinone and naphthyridoncarboxylic acids | BAYER AG (DE) | 1986-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | POLB 1445/4885LMNA 2816/4885ALDH1A1 2165/4885 |
| US-10231932-B2 | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases | CFTR, CLIC1, PKD2 | POLB 1569/4885LMNA 1433/4885ALDH1A1 1941/4885 |
| US-20210308053-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | CFTR, SLC26A4, PKD1 | POLB 3588/4885LMNA 3070/4885ALDH1A1 2648/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | POLB 1445/4885LMNA 2816/4885ALDH1A1 2165/4885 |
| US-20200338063-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | CFTR, CLCN2, CLIC1 | POLB 2331/4885LMNA 2140/4885ALDH1A1 2559/4885 |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | POLB 1445/4885LMNA 2816/4885ALDH1A1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.